2Wagner N, Rotthauwe HW. Hepatitis C contributes to liverdisease in children and adolescents with hemophilia [J]. Klin Padiatr, 1994, 206(1):40-44
3Sengupta B, De M, Lahiri P,et al. Sero-surveillance of transmissible hepatitis B & C viruses in asymptomatic HIV infection in haemophilics [J], Indian J Med Res, 1992, 95(11):256-258
5[2]Moor ACE, Dubbelman TMAR, Van Steveninck, et al . Transfusiontransmitted diseases: risk, prevention and perspectives. Eur J Hamatol,1999,62( 1 ): 1-18.
6[4]Reichard O, Norkrans G, Fryden A, et al . Comparison of 3 quantitative HCV RNA assays,accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis, 1998,30(5):441-446.
7[5]Olmedo E, Costa J, Lopez-Labrador FX, et al . Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. J Med Virol, 1999,58( 1 ) :35-43.
8[6]Horn T, Chang CA, Urdea MS. Chemical synthesis and characterization of branched oligodeoxyribonucleotides (bDNA) for use as signal amplifiers in nucleic acid quantification assays. Nucl Acids Res, 1997,25 (23): 4842-4849.
9[7]Holland P, Abramson R, Watson R, et al . Detectioon of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA, 1991,88(16): 7276-7280.
10[8]Pisani G,Cristiano K,Saldanha J, et al .External quality assessment for the detection of blood-borne viruses in plasma by nucleic acid amplification technology: the first human immumodeficiency virus and hepatitis B virus studies (HIV EQA/1 and HBV EQA/1) and the fifth hepatitis C virus study (HCV EQA/5). Vox Sang,2004,87(2) :91-95.
6FRANCHINI M, LIPPI G. Recombinant factor VIII concentrates[ J].Semin Thromb Hemost,2010,36(8) :930-931.
7JSHI, YZHAO,JU, JSUN,et al. Safety and efficacy of a sucrose-for-mulated recombinant factor VIII product for the treatment of previouslytreated patients with haemophilia A in China [ J]. Haemophilia,2007,13: 351-356.
8L ZHANG, YZHAO, JSUN, et al. Clinical observation on safety andefficacy of a plasma- and albumin-free recombinant factor VIII for on-demandtreatment of Chinese patients with haemophilia A[ J]. Haemo-philia,2011, 17; 191-195.
9RENCHI YANG, YONGQIANG ZHAO, et al. Safety and Efficacy ofMoroctocog Alfa (AF-CC) ( XYNTHA) in Minimally Treated andPreviously Treated Chinese Patients with Haemophilia A[ J]. Haemo-philia 2012 in-press.
10R. WU,K. -H. LUKE,et al. Low dose secondary prophylaxis reducesjoint bleeding insevere and moderate haemophilic children : a pilotstudy in China[ J]. Haemophilia. 2011 , 17:70-74.
